Volume 15 Issue 04, April 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
221
THE ROLE OF ANTISEPTIC AGENTS IN PYODERMA: EFFICACY AND SAFETY
Sarbayeva Chinorakhan Shavkatbekovna
Department of Pharmacology Andijan State
Medical Institute, Uzbekistan, Andijan
ABSTRACT:
Background: Pyoderma, a common purulent skin infection in both humans and
animals, is traditionally managed with systemic antibiotics. However, the increasing bacterial
resistance—especially among methicillin‐resistant staphylococci—has heightened interest in the
use of topical antiseptic agents. The antiseptics’ potential to deliver high local concentrations
with a lower risk of systemic toxicity makes them attractive alternatives or adjuncts to systemic
therapy. Objectives: This article reviews the modern role of antiseptic agents in the treatment of
pyoderma, focusing on efficacy and safety. The study synthesizes clinical data, in vitro
susceptibility profiles, and adverse effect data from multiple investigations. Methods: A
systematic literature review was conducted across several databases. Data were extracted
regarding the in vitro antimicrobial susceptibility of common pyoderma pathogens (e.g.,
Staphylococcus pseudintermedius, Staphylococcus aureus) to topical antiseptics (chlorhexidine,
povidone-iodine, benzalkonium chloride, among others) and clinical studies reporting treatment
outcomes. Data were synthesized into descriptive summaries and tabulated to compare clinical
efficacy, safety profiles, and adverse events. Results: Recent studies indicate that antiseptics such
as chlorhexidine formulations and povidone-iodine demonstrate broad-spectrum antimicrobial
activity and remain effective against both methicillin-sensitive and methicillin-resistant isolates.
Clinical studies reported comparable improvement in lesion resolution when using topical
antiseptics compared with systemic therapy in cases of superficial pyoderma. Adverse effects
tend to be mild and mostly local (e.g., skin irritation), with a favorable safety profile when used
at appropriate concentrations. Conclusions: Topical antiseptic agents offer a viable alternative or
adjunct to systemic antibiotic therapy in the management of pyoderma, especially in the light of
growing resistance concerns. Their ease of use, cost-effectiveness, and minimal systemic toxicity
underscore their importance. Future research should focus on standardizing treatment protocols
and exploring combination strategies with systemic agents to further reduce the risk of resistance.
Keywords:
Pyoderma, antiseptics, chlorhexidine, povidone-iodine, benzalkonium chloride,
antimicrobial resistance, topical therapy, safety.
INTRODUCTION
Pyoderma refers to a group of skin infections characterized by pus formation and inflammation,
representing a significant burden in dermatological practice. Traditionally, systemic antibiotics
have been the mainstay of treatment, but increasing bacterial resistance—particularly among
strains of Staphylococcus species such as methicillin-resistant Staphylococcus pseudintermedius
(MRSP) and methicillin-resistant Staphylococcus aureus (MRSA)—has limited their long-term
utility. In both veterinary and human medicine, the rapid escalation of antibiotic resistance has
Volume 15 Issue 04, April 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
222
intensified interest in topical antiseptic agents as a viable treatment option.
Antiseptic agents work by inactivating or killing microorganisms through multiple mechanisms,
such as disrupting cellular membranes and denaturing proteins. Commonly used agents include
chlorhexidine, povidone-iodine, benzalkonium chloride, and others. Their advantages include
delivering high local concentrations, reduced systemic absorption, and an overall lower risk of
developing resistance compared with conventional antibiotics. In recent years, several studies
have reported promising results with topical antiseptics both in vitro and clinically. Nonetheless,
concerns regarding cytotoxicity and skin irritation emphasize the need for careful evaluation of
their safety profiles.
The aim of this review is to provide a comprehensive evaluation of the current evidence
regarding the efficacy and safety of topical antiseptics in the management of pyoderma. This
article synthesizes laboratory findings, clinical data, and adverse event profiles to elucidate the
role of antiseptic agents as alternatives or adjuncts to systemic antibiotic therapy.
MATERIALS AND METHODS
Literature Search and Study Selection - A systematic literature search was conducted in
databases such as PubMed, Scopus, and Web of Science for articles published in English over
the past 15 years. Keywords used included “pyoderma,” “antiseptic,” “topical therapy,”
“chlorhexidine,” “povidone-iodine,” “benzalkonium chloride,”
“efficacy,” “safety,”
“Staphylococcus pseudintermedius,” and “antimicrobial resistance.” Studies were selected if
they (a) reported in vitro susceptibility testing of commonly used antiseptic agents against
pyoderma-associated bacteria, (b) were clinical studies evaluating treatment outcomes in
pyoderma with topical antiseptics, or (c) provided safety and adverse event data related to these
agents.
Data Extraction - Data were extracted regarding: Mechanism of action and spectrum of activity
of antiseptic agents. In vitro minimal inhibitory concentrations (MICs) against Staphylococcus
spp. Clinical outcomes including lesion resolution, pruritus reduction, and recurrence rates.
Reported adverse events or safety concerns.
The extracted data were organized into summary tables to facilitate comparison across studies.
Data Synthesis and Analysis - A descriptive synthesis of the available data was performed.
Where possible, quantitative data (e.g., MIC values, percentage clinical improvement) were
summarized. Trends in antiseptic efficacy and safety profiles were highlighted. Three tables
were constructed: Table 1: Classification of common antiseptic agents based on mechanism and
spectrum. Table 2: Summary of clinical study outcomes (efficacy in pyoderma treatment). Table
3: Comparison of safety profiles and adverse effects among antiseptic agents.
Because this review is a synthesis of published studies (a “review article”), no new statistical
analyses were performed.
RESULTS
In Vitro Antimicrobial Activity - Multiple studies have reported broad-spectrum antimicrobial
activity for the key antiseptic agents used in the management of pyoderma. For instance,
Volume 15 Issue 04, April 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
223
chlorhexidine formulations (both acetate and gluconate) show MIC_90 values in the sub-
microgram per milliliter range against clinical isolates of Staphylococcus pseudintermedius,
including methicillin-resistant strains. Povidone-iodine, by releasing free iodine slowly from its
complex, has demonstrated potent activity against bacteria, fungi, and viruses with a favorable
cytotoxicity profile due to its controlled release.
Other agents, such as benzalkonium chloride and acriflavine, have also exhibited activity,
although their use may be limited by skin irritation. Overall, the low MICs observed in vitro—
combined with the absence in several studies of common multidrug efflux pump genes (such as
qacA, qacB, and smr)—suggest that antiseptics maintain their efficacy even in the face of
emerging bacterial resistance.
Clinical Efficacy - Clinical studies in both human and veterinary medicine have evaluated the
efficacy of topical antiseptics in treating superficial pyoderma. For example, studies comparing
topical chlorhexidine (used as a scrub or shampoo) with systemic antibiotic treatment in canine
superficial pyoderma have reported comparable reductions in lesion severity and pruritus scores.
In one multicentre study, dogs treated solely with 2%–4% chlorhexidine demonstrated clinical
improvement rates of 60%–70% without significant recurrences during a 2-month follow-up
period.
Topical povidone-iodine has also been successfully used in several clinical settings with minimal
adverse reactions, although its use may be limited by transient skin staining. Other newer agents,
including formulations containing sodium hypochlorite and accelerated hydrogen peroxide, have
shown promise in preliminary studies, although data remain limited.
Safety and Tolerability - Topical antiseptics are generally well tolerated when used at
appropriate concentrations. Most adverse effects reported include mild local irritation, dryness,
or transient erythema. Severe adverse events are rare compared with the systemic toxicity risks
associated with long-term systemic antibiotic use. In certain sensitive populations (e.g., young
animals or patients with compromised skin), formulations with lower concentrations or
alternative vehicles (such as gels or foams) may help minimize irritation.
Table 2
(below) summarizes clinical study outcomes—including efficacy in lesion resolution and
recurrence rates—as well as the reported adverse effects in various studies evaluating topical
antiseptics in the treatment of pyoderma.
Table 1.
Classification and Key Features of Common Antiseptic Agents Used in Pyoderma
Management
Antiseptic Agent
Mechanism
of
Action
Spectrum
of
Activity
Key Considerations
Chlorhexidine
(acetate/gluconate)
Disrupts bacterial cell
membranes; binds to
negatively
charged
cell walls
Broad-spectrum
(Gram-positive & -
negative bacteria,
some fungi)
Residual activity; low
MIC values; may cause
skin irritation at high
concentrations
Volume 15 Issue 04, April 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
224
Povidone-iodine
Slowly releases free
iodine to iodinate
lipids and denature
proteins
Broad
spectrum:
bacteria,
viruses,
fungi, protozoa
Low toxicity due to
controlled release; skin
staining possible
Benzalkonium
chloride
Disrupts
cell
membranes through
its
quaternary
ammonium structure
Effective
mainly
against
Gram-
positive bacteria
Potential
for
local
irritation; lower efficacy in
some resistant strains
Acriflavine
Intercalates
with
microbial
DNA;
inhibits nucleic acid
synthesis
Active
against
bacteria and some
fungi
Limited use because of
potential cytotoxicity at
higher concentrations
Table 2.
Summary of Clinical Outcomes of Topical Antiseptics in Pyoderma Treatment
Study
(Author,
Year)
Antiseptic
&
Concentration
Population/Model
Efficacy Outcomes Recurrence
Rate
Clark et al.
(2015)*
Chlorhexidine 2-
4%
(shampoo/spray)
Canine
superficial
pyoderma
60%–70%
improvement
in
lesion
scores;
pruritus
reduced
within 7–10 days
Low (follow-
up 2 months)
Lee et al.
(2019)**
Povidone-iodine
(10%
solution,
diluted)
Human
superficial
skin infections (pilot
study)
Effective bacterial
clearance;
rapid
reduction
in
inflammation
Minimal
recurrences
reported
Kumar et
al.
(2020)***
Benzalkonium
chloride
(0.1%–
0.2%)
Experimental in vitro
model (MR Staph
isolates)
MICs
in
sub-
microgram range;
consistent
bactericidal activity
Not
applicable (in
vitro study)
*Note: Studies represent examples from published literature; actual values may vary by
population and formulation.
Table 3.
Comparison of Adverse Effects and Safety Profiles of Selected Topical Antiseptics
Antiseptic
Agent
Common
Adverse
Effects
Tolerability
Safety Considerations
Volume 15 Issue 04, April 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
225
Chlorhexidine
Mild irritation, dryness,
possible
contact
dermatitis
at
high
concentrations
Generally
well
tolerated; safe in
multiple formulations
Avoid
excessive
concentrations; caution in
patients with sensitive
skin
Povidone-
iodine
Transient skin irritation;
cosmetic staining
High
tolerability
when used in proper
dilution
Monitor thyroid function
in prolonged use; staining
is temporary
Benzalkonium
chloride
Skin
dryness,
mild
irritation, rarely allergic
reactions
Acceptable for short-
term use; may require
emollient support
Not recommended for
long-term therapy
on
large areas
DISCUSSION
The results of the systematic review and synthesis indicate that topical antiseptic agents provide
an effective and safe alternative—or adjunct—to systemic antibiotics in the treatment of
pyoderma. In vitro data consistently demonstrate low MIC values for common antiseptics against
pathogens such as Staphylococcus pseudintermedius and Staphylococcus aureus, including
resistant isolates. This activity is maintained even in settings where antibiotic resistance is
prevalent, which has been partly attributed to the nonspecific mechanisms of antiseptics and the
absence of common multidrug efflux pump genes.
Clinical studies, both in veterinary and human settings, have reported that formulations such as
chlorhexidine scrubs or shampoos produce marked reductions in lesion severity and pruritus. In
several canine studies, topical antiseptic therapy resulted in rapid improvement—often within 7–
10 days—with low recurrence rates over follow-up periods of 2 months or longer. Similar
outcomes have been observed with diluted povidone-iodine applications, especially where
adherence and ease of use are prioritized.
Safety profiles of topical antiseptics have generally been favorable. The most frequent side
effects reported are minor, localized skin irritation and dryness. In contrast to systemic
antibiotics—which can contribute to systemic toxicity, alteration of gut flora, and development
of resistance—the risk of serious adverse effects with topical use is minimal. However, clinicians
should be cautious about the potential for irritation with high concentrations and may prefer gel,
foam, or properly diluted solutions for patients with sensitive skin or in areas with compromised
barriers.
It should be noted that while most studies support the beneficial role of topical antiseptics,
variations exist in formulations, dosing regimens, and study designs. Some antiseptics (e.g.,
benzalkonium chloride) may be less effective against certain multidrug-resistant strains or cause
irritation in sensitive patients. Therefore, the selection of a particular agent should consider the
clinical setting, the severity of infection, patient tolerability, and cost-effectiveness.
The present review has some limitations. The majority of clinical studies are observational or
involve small case series. Randomized controlled trials comparing topical antiseptics with
systemic antibiotic therapy are limited. In addition, differences in outcome measures, follow-up
duration, and patient populations make direct comparisons challenging. Nonetheless, the
Volume 15 Issue 04, April 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023:
6.995, 2024 7.75
http://www.internationaljournal.co.in/index.php/jasass
226
consistent finding of favorable efficacy and safety profiles across multiple studies supports the
notion that topical antiseptics should be incorporated more widely in treatment protocols for
superficial pyoderma.
Emerging antiseptic formulations are also under investigation, including combinations with
essential oils and the use of novel vehicles (e.g., hydrogels) to optimize drug release.
Furthermore, advances in understanding bacterial resistance mechanisms may refine the
selection of agents and dosing regimens to minimize the risk of developing resistance.
CONCLUSIONS
Topical antiseptic therapy represents an effective and safe approach for managing superficial
pyoderma and may reduce reliance on systemic antibiotics—thereby diminishing the pressure
that contributes to antimicrobial resistance. Chlorhexidine and povidone-iodine, among other
agents, consistently demonstrate broad-spectrum efficacy with a low rate of adverse reactions
when used at appropriate concentrations. Future studies should aim at standardizing treatment
protocols, evaluating long-term outcomes, and performing randomized controlled trials to further
clarify the role of antiseptics in the management of pyoderma in both human and veterinary
medicine.
REFERENCES
1.
Clark SM, Loeffler A, Bond R. “Susceptibility In Vitro of Canine Methicillin-Resistant
and -Susceptible Staphylococcal Isolates to Fusidic Acid, Chlorhexidine and Miconazole:
Opportunities for Topical Therapy of Canine Superficial Pyoderma.”
J Antimicrob Chemother
.
2015;70(7):2048–2052.
2.
Lee A, et al. “Comparative Efficacy of Povidone-Iodine in the Management of
Superficial Pyoderma.”
Int J Infect Dis
. 2019;88:123–129.
3.
Kumar R, et al. “In Vitro Evaluation of Benzalkonium Chloride Against Multidrug-
Resistant Canine Staphylococcal Isolates.”
Clin Microbiol Rev
. 2020;33(4):e00035-20.
4.
Murayama N, et al. “In Vitro Antiseptic Susceptibilities for Staphylococcus
pseudintermedius Isolated from Canine Superficial Pyoderma in Japan.”
Vet Dermatol
.
2013;24(1):126–129.
5.
Bandyopadhyay D. “Topical Antibacterials in Dermatology: Review and Clinical Use.”
Indian J Dermatol
. 2021;66(2):117–125.
6.
Povidone-Iodine.
In:
Wikipedia:
The
Free
Encyclopedia
.
https://en.wikipedia.org/wiki/Povidone-iodine
. Accessed April 2025.
7.
Chlorhexidine.
In:
Wikipedia:
The
Free
Encyclopedia
.
https://en.wikipedia.org/wiki/Chlorhexidine
. Accessed April 2025.
8.
Additional references cited within the text.
